



European Federation of Pharmaceutical
Industries and Associations

Press Release

13 July 2016

EFPIA Japan

EFPIA Japan contribute JPY123 million to Kumamoto Earthquake relief efforts

TOKYO—13 July 2016— EFPIA Japan (Chairman: Dr. Carsten Brunn) announces today that its member companies' contributions to the ongoing Kumamoto Earthquake relief efforts now total JPY 123 million. These contributions from EFPIA member companies to the victims of the disaster have been made through various organisations, including the [Kumamoto prefectural government](#), the [Japanese Red Cross Society](#), and [Japan Platform](#).

Many member companies have used matching gift programmes, whereby the company makes a donation of the same amount as employees' personal and voluntary donations. Around 40 per cent of the total amount was donated together by the employees and companies through these matching gift programmes.

EFPIA member companies have made not only financial contributions, but have also provided consumer healthcare products, food and water, towels and other goods to the affected areas. In addition, companies have supported employees' participation in volunteer activities related to the relief efforts.

EFPIA member companies extend their deepest sympathy to the victims of the Kumamoto earthquake on 14 April, 2016 and the subsequent seismic activity in Kyushu. We hope for the earliest possible recovery of the affected areas.

###

EFPIA Japan.

Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265

Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

About European Federation of Pharmaceutical Industries and Associations (EFPIA):

EFPIA, EFPIA Japan's partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 42 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

About EFPIA Japan:

Established in 2002, EFPIA Japan represents 24 R&D-based European pharmaceutical companies operating in Japan. In 2015, combined sales from the member companies accounted for roughly 24% of the pharmaceutical market in Japan.

The mission of EFPIA Japan is to "Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines". EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

For more information please visit:

<http://www.efpia.eu> (EFPIA)

<http://efpia.jp/English/index-e.html> (EFPIA Japan)

Contact:

Tetsu Owari, Vice Chair of EFPIA Japan Public Relations Committee

ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017

Boehringer Ingelheim Japan, Inc.

TEL: 03-6417-2223

Mail: tetsuya.owari@boehringer-ingelheim.com

Yumiko Kurahashi, Vice Chair of EFPIA Japan Public Relations Committee

Marunouchi Trust Tower 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005

AstraZeneca K.K.

TEL: 03-6268-2800

Mail: Yumiko.Kurahashi@astrazeneca.com

###